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Abstract
AIM: To deduce strategic guidelines of gastric mucosa
associated lymphoid tissue lymphoma (MALTOMA) by
evaluating the long-term outcome of patients in respect to
various treatment modalities.
METHODS: A total of 55 patients with MALTOMA from May
1992 to August 2002 were retrospectively reviewed.
RESULTS: Complete remission was obtained in 24 (82.8%)
of 29 patients treated with anti Helicobacter pylori (H pylori)
regimen only. The duration to reach complete remission
was 12 months (85 percentile, 2-33 months). Five patients
showed complete remission with radiation therapy (26-86
months). Two of them were H pylori treatment failure cases.
CONCLUSION: H pylori eradication is an effective primary
treatment option for low grade MALTOMA and radiation
therapy could be considered in patients with no evidence of
H pylori infection or who do not respond to H pylori eradication
therapy 12 months after successful eradication.
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INTRODUCTION
In 1983, Isaacson and Wright introduced the term mucosa
associated lymphoid tissue lymphoma (MALTOMA) to
characterize primary low grade gastric B-cell lymphoma and
immunoproliferative small-intestinal disease[1]. Subsequently,
the definition of MALTOMA was extended to include several
other extranodal low grade B-cell lymphomas, with a similar
histology to Payer’s patches, including those of the salivary
gland, lung, and thyroid, but gastric form is the most common
and best characterized MALTOMA[2].
     Low grade MALTOMA is composed of small cells with
dense nuclear chromatin and a low proliferation fraction, the
converse is true for diffuse large B cell lymphoma. Low grade
gastric MALTOMA is a neoplasia with a very indolent course
and an excellent prognosis. It has a tendency to remain
localized to the gastric wall and seldom involves lymph nodes
and bone marrow.
    In the past, primary low grade gastric MALTOMA was
treated with surgery in the same way as adenocarcinoma. This
often necessitated a total gastrectomy due to the multi-focal or
diffuse nature of gastric lymphomas. Since the introduction of
H pylori concept, the association of this bacterium with
chronic active gastritis, peptic ulcer and gastric cancer has been
demonstrated[3-5]. Furthermore, H pylori is suggested to be
associated with low-grade gastric MALTOMA. It was proposed
that low grade gastric MALTOMA be formed by the immune
response to H pylori infection in the gastric mucosa[6,7]. The
discovery of a causal role for H pylori in the development of
gastric marginal zone lymphoma of the MALT type has
dramatically altered the therapeutic approach to patients with
early stage disease[8,9]. According to recent data, durable complete
remissions might be achieved in up to 80% of patients with
early stage MALTOMA following eradication of the bacteria[9].
In patients who failed to respond to H pylori eradication or had
low grade gastric MALTOMA without H pylori infection,
radiotherapy, chemotherapy or surgery has been tried.
    However, the long-term follow-up result of H pylori
eradication on low grade MALT lymphoma has been seldom
reported. Furthermore, a clear-cut time is difficult to define
the failure to H pylori eradication therapy and currently there
has been no standard guidelines to assess the result of eradication
therapy. Also the time interval to perform endoscopic
examination to evaluate histologic and morphologic remission
is unclear. Consequently, a suitable strategic guideline to decide
subsequent treatment option when one fails has not been well
proposed. We aimed to evaluate the long-term outcome of
patients with low grade gastric MALTOMA in respect to
various treatment modalities. We also tried to deduce suitable
strategic guidelines to treat low grade gastric MALTOMA.
MATERIALS AND METHODS
Patients
We retrospectively studied 55 patients with primary low grade
gastric MALTOMA aged 23 to 74 years from May 1992 to
August 2002. All the patients were pathologically confirmed
as low grade gastric MALTOMA. The diagnosis of low grade
gastric MALTOMA was made according to the criteria of
Isaacson[10] and scoring system of Wotherspoon et al[11]. The
initial staging procedures included a complete physical
examination, chest roentgenogram, bone marrow examination,
abdominal CT scan and endoscopic ultrasonography (EUS).
Methods
We evaluated the patients’ initial presenting symptoms and
the status of H pylori infection. H pylori infection was
diagnosed by rapid urease test (CLOTM, Delta West, Bentley,
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Western Austria), and/or histologic examination. H pylori status
was considered to be positive if any of the two tests was
positive. Endoscopic findings included the shape, size, location
and number of lesions. Gross phenotype was classified
according to the endoscopic features into seven types: 1)
gastritis: only mucosal color change, 2) granular: small nodules
on the lesion, 3) ulcerative: one or more ulcerations, 4)
ulceroinfiltrative: one or more ulcerations with surrounding
mucosal infiltration, 5) depressed: depressed or EGC IIc like
lesion, 6) protruding: elevated or polypoid, and 7) mixed, and
then was categorized into diffuse and localized type according
to the pattern of distribution.
RESULTS
Clinical and endoscopic features of patients
The male to female ratio was 1:1.3. The mean age of the
patients was 47.8 years (23-74). All but three of the patients
were symptomatic at presentation. The main symptoms were
abdominal pain (56.4%), indigestion (23.6%), epigastric
discomfort (12.7%) and vomiting (1%). A total of 48 (48/53,
90.5%) met the case definition for H pylori positivity (Table
1). When each test was considered individually, H pylori
infection was detected by histology and rapid urease test in 42
(87.5%) and 39 (81.3%) patients, respectively. Initial endoscopic
findings are summarized in Table 2.
Table 1  Clinical features of patients and H pylori state (n=55)
Age (years)         47.8±11.3 ( 23-74 )
Sex         Male:Female=24:31
H pylori statusa         Positive 48 (90.5%)
        Negative   5 (9.5%)
aExcluding two cases of unknown H pylori status.
Table 2  Endoscopic findings and location of low grade
MALTOMA (n=55)
Location   No. of cases (%)      Findings           No. of cases (%)
Body only        21 (38.2)         Ulcerative   15 (27.3)
Antrum only        11 (20.0)         Mixed   15 (27.3)
Antrum & body       20 (36.4)         Ulceroinfiltrative   10 (18.2)
Fundus/Cardia         3 (5.4)         Depressed      6 (10.9)
        Gastritis      5 (9.1)
        Protruding      3 (5.5)
        Granular      1 (1.8)
Treatment modalities and outcomes
Treatment modalities included H pylori eradication, surgery,
radiotherapy and combination therapy (Table 3). A total of
twenty nine patients were treated with H pylori eradication
therapy (omeprazole + amoxicillin + metronidazole or
clarithromycin for 2 weeks). All but one was positive in urease
test or histologic examination for H pylori. Endoscopic
ultrasonography was done before H pylori eradication and cases
with lymph node metastasis or involvement beyond the
submucosal layer were excluded. For determination of the
response, two months after the end of eradication therapy,
biopsy specimens were collected from the multiple sites
including the lesion for histologic examination. One additional
specimen was obtained for rapid urease test. For the remission
failure case, a repeat endoscopy was performed every two to
three months until complete remission was achieved. In cases
with complete remission, endoscopic examination and biopsy
were performed every 6-12 months. Overall H pylori
eradication rate was 96.4% (27/28). Complete remission of
low grade MALTOMA was achieved in 24 out of 29 cases
(82.8%). The median time to get complete remission was 4
months (2-33) (Table 3). In terms of histologic remission of
the low grade gastric MALTOMA, the mucosal lesions
changed to atrophic or endoscopically normal appearance
(Figure 1). There were five treatment failures to H pylori
eradication therapy. Radiation treatment was given in two
patients who failed to respond to anti H pylori treatment after
6 months and 9 months of follow-up, respectively. One
underwent operation. They all had complete remission in the
subsequent follow-up. The remaining two patients were
recommended to receive other treatment with persistence of
localized MALTOMA.
Figure 1  A: A case with irregular ulceration on the anterior wall
of antrum before eradication. B: Three months after H pylori
eradication therapy, ulceration was disappeared. C: A case with
mucosal nodularities on the posterior wall of the upper body
before eradication. D: Two months after H pylori eradication





     Sixteen patients underwent surgery, including 11 total
gastrectomies and 5 subtotal gastrectomies (Table 3). Most of
them were treated by surgery because they were suspected to
have lymph node metastasis or infiltration beyond the
submucosal layer in endoscopic ultrasonographic examination.
Among the sixteen patients, 4 patients showed lymph node
metastasis. Three patients received additional radiation therapy
or chemotherapy after surgery because of lymph node metastasis
or perigastic fat infiltration of low grade gastric MALTOMA.
    Five patients received radiation therapy. These cases
included two patients with H pylori negativity, two patients
with failure to H pylori eradication, and one case with
recurrence in remnant stomach after surgery (Table 3). The
median radiation dose was 30.6 Gy (range 30-39) with a daily
fraction of 1.5-1.8 Gy.
     The comparative study among different endoscopic types
of low grade MALT lymphoma patients who showed failure
to eradication treatment disclosed no significant correlation.
However, the lesion of localized mass type showed the
tendency to higher treatment failure (Table 4).
Table 3  Initial treatments and outcomes of low grade MALTOMA
         H pylori eradication      Surgery      Radiotherapy
        (n=29)          (n=16)              (n=5)
Complete     24 (82.8%)       16 (100%)     5 (100%)
remission (%)
Failure (%)       5 (17.2%)          0      0
Recurrence (%)       1 (4.2%)          1      0
Median follow-     24 (2-74)    46.5 (12-120)  35.5 (26-86)
up (months)




Table 4  Failures of H pylori eradication treatment according to
endoscopic findings
Endoscopic types Treatment cases Failure cases (%a)
Diffuse 13        1 (17.7)b
Gastritis   2        0 (0)
Granular   1        0 (0)
Mixed 10        1 (10.0)
Localized 16        4 (25.0)a
Ulcerative   8        2 (25.0)
Ulceroinfiltrative   3        1 (33.3)
Depressed   4        0 (0)
Protruding   1        1 (100.0)
Total 29        5 (17.2)
aFailure rate of each endoscopic type, bP>0.05 by c2 test.
DISCUSSION
The relationship between H pylori and low grade gastric
MALTOMA is strong, and therefore treatment strategies are
aimed at H pylori eradication in early stages. Recently, durable
complete remissions have been supposed to achieve in up to
80% of patients with early stage MALTOMA following
eradication of the bacteria[9]. In the largest MALTOMA study
to date, 120 patients with early stage low grade gastric
MALTOMA were treated with H pylori eradication therapy
and followed[12]. After a mean follow-up period of 48 months,
81% of patients had complete remission. Relapse after
complete remission occurred in less than 10% of cases, and
whether this was always caused by H pylori reinfection has
been unknown[13-24]. Follow-up is essential in patients with
MALTOMA treated with H pylori eradication therapy.
Endoscopic follow-up with biopsy for histology and H pylori,
and EUS at least yearly after remission was recommended[12,25].
Because some residual cells lay dormant after clinical and
histological remission was achieved, some investigators
insisted that molecular studies should be included in addition
to histologic study[20]. At present, histologic study is considered
as the gold standard.
     Because eradication therapy is never 100% successful, it is
also important to choose the most suitable additional treatment
for treatment failure. MALTOMA that was not H pylori
positive or did not respond to eradication therapy could be
treated with surgery, radiation, or chemotherapy. Radical
gastrectomy has 5- and 10-yr survival rates of 90% and 70%,
but leads to significant morbidity[26]. Monotherapy with alkylating
agents was tried in MALTOMA patients who did not respond
to H pylori eradication therapy. In this study, remission could
be achieved with chlorambucil in only 58% of the nonresponding
patients to H pylori eradication therapy[25].
     Our results showed 82.8 % of remission induction in low
grade gastric MALTOMA by H pylori eradication alone with
a single relapse. About 50% of patients with low grade gastric
MALTOMA showed complete remission by 4 months after
H pylori eradication. However, delayed response by up to 33
months occurred in one case. Overall, complete remission was
achieved within 12 months in 85 percentile. We propose that
it is necessary to wait for 12 months after initial eradication
therapy of H pylori to define the time for H pylori eradication
failure, because relapse is relatively rare after 12 months and
nearby all the cases would have complete remission by 12
months. In addition, other treatment modalities could be used
12 months after initial H pylori eradication therapy, such as
radiation therapy, surgery or chemotherapy.
     A recent series from the memorial Sloan-Kettering Cancer
Center and Yonsei Cancer Center reported a 100% complete
remission rate with radiation alone. Especially, radiation
therapy was chosen in the management of low grade gastric
MALTOMA in patients with no evidence of H pylori infection
or who showed no response to H pylori eradication therapy[27,28].
In our study, complete remission was obtained in all the patients
after various treatment modalities. All the patients who received
radiotherapy tolerated the treatment well and completed the
treatment course without significantly acute or delayed
toxicities. Radiation therapy was superior to surgery or
chemotherapy because it had significant advantages of gastric
preservation and lower morbidity.
      Our results provide further supports to the recommendation
by Issacson and Spencer that eradication of H pylori is harmless
and inexpensive and should be the first-line treatment for
localized low grade gastric MALTOMA. If no response is
observed by 12 months after eradication therapy, radiotherapy
should be considered.
     Several investigators evaluated endoscopic appearance of
primary gastric lymphoma[29,30]. In low grade gymphoma,
endoscopic findings were often interpreted as a benign
condition, in contrast to high grade lymphoma, for which
carcinoma was the most frequently suspected diagnosis. Our
results were consistent with previous reports that low grade
gastric MALTOMA was found at a relatively high frequency
(94.6%) in the middle third of the stomach[31]. The most
frequent endoscopic appearance of gastric lymphoma was
ulceration, while the finding of polypoid lesions or other forms
(as gastritis or erosions) had a lower frequency[32]. Also in this
study, the majority of the endoscopic features of low grade
gastric MALTOMA was superficial, such as shallow ulceration
or mixed type, and was multiple rather than single. But these
cases also exhibited varied pictures. In terms of the result of
H pylori eradication therapy, we did not see any correlation
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with the endoscopic findings. It might be due to the small
number of cases of H pylori eradication failure and complexity
of endoscopic findings of low grade MALTOMA. However,
the lesion of localized mass type showed the tendency to higher
treatment failure (Table 4). Nevertheless, if we consider the
fact that high grade lymphoma is often accompanied by deep
ulceration or protruding mass in the stomach, our results might
be valuable on the presumption that mixed type MALTOMA
might exist which is responsible for the treatment failure.
REFERENCES
1 Isaacson P, Wright DH. Malignant lymphoma of mucosa-asso-
ciated lymphoid tissue. A distinctive type of B-cell lymphoma.
Cancer 1983; 52: 1410-1416
2 Zhou Q, Xu TR, Fan QH, Zhen ZX. Clinicopathologic study of
primary intestinal B cell malignant lymphoma. World J
Gastroenterol 1999; 5: 538-540
3 Marshall BJ ,  Warren JR. Unidentified curved bacilli in the stom-
ach of patients with gastritis and peptic ulceration. Lancet 1984;
16: 1311-1315
4 NIH Consensus conference. Helicobacter pylori in peptic ulcer
disease. NIH Consensus Development Panel on Helicobacter py-
lori in Peptic Ulcer Disease. JAMA 1994; 272: 65-69
5 Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman
JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the
risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131
6 Wyatt JI, Rathbone BJ. Immune response of the gastric mucosa to
Campylobacter pylori. Scand J Gastroenterol Suppl 1988; 142: 44-49
7 Stolte M, Eidt S. Lymphoid follicles in antral mucosa: immune
response to Campylobacter pylori? J Clin Pathol 1989; 42: 1269-1271
8 Isaacson PG. Gastric MALT lymphoma: from concept to cure.
Ann Oncol 1999; 10: 637-645
9 Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer
B, Wundisch T, Ehninger G, Stolte M, Bayerdorffer E. Cure of
Helicobacter pylori infection and duration of remission of low-
grade gastric mucosa-associated lymphoid tissue lymphoma. J
Natl Cancer Inst 1997; 89: 1350-1355
10 Isaacson PG. Gastrointestinal lymphoma. Hum pathol 1994; 25:
1020-1029
11 Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de
Boni M, Isaacson PG. Regression of primary low-grade B-cell
gastric lymphoma of mucosa-associated lymphoid tissue type
after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577
12 Stolte M, Bayerdorffer E, Morgner A, Alpen B, Wundisch T,
Thiede C, Neubauer A. Helicobacter and gastric MALT lymphoma.
Gut 2002; 50: 19-24
13 Isaacson PG, Diss TC, Wotherspoon AC, Barbazza R, De Boni
M, Doglioni C. Long-term follow-up of gastric MALT lymphoma
treated by eradication of H pylori with antibodies. Gastroenterol-
ogy 1999; 117: 750-751
14 Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology
to treatment. Lancet Oncol 2002; 3: 97-104
15 Roggero E, Zucca E, Pinotti G, Pascarella A, Capella C, Savio A,
Pedrinis E, Paterlini A, Venco A, Cavalli F. Eradication of
Helicobacter pylori infection in primary low-grade gastric lym-
phoma of mucosa-associated lymphoid tissue. Ann Intern Med
1995; 122: 767–769
16 Savio A, Franzin G, Wotherspoon AC, Zamboni G, Negrini R,
Buffoli F, Diss TC, Pan L, Isaacson PG. Diagnosis and posttreat-
ment follow-up of Helicobacter pylori-positive gastric lymphoma
of mucosa-associated lymphoid tissue: histology, polymerase
chain reaction, or both? Blood 1996; 87: 1255–1260
17 Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C,
Schulz H, Kraemer W, Boersch G, Rohde P, Seifert E, Stolte M,
Bayerdoerffer E. Regression of gastric MALT lymphoma after
eradication of Helicobacter pylori is predicted by endosonographic
staging. MALT Lymphoma Study Group. Gastroenterology 1997;
113: 1087–1090
18 Montalban C, Manzanal A, Boixeda D, Redondo C, Alvarez I,
Calleja JL, Bellas C. Helicobacter pylori eradication for the treatment
of low-grade gastric MALT lymphoma: follow-up together with
sequential molecular studies. Ann Oncol 1997; 8(Suppl 2): 37-39
19 Papa A, Cammarota G, Tursi A, Gasbarrini A, Gasbarrini G.
Helicobacter pylori eradication and remission of low-grade gas-
tric mucosa-associated lymphoid tissue lymphoma: a long-term
follow-up study. J Clin Gastroenterol 2000; 31: 169–171
20 Montalban C, Santon A, Boixeda D, Redondo C, Alvarez I,
Calleja JL, de Argila CM, Bellas C. Treatment of low grade gas-
tric mucosa-associated lymphoid tissue lymphoma in stage I
with Helicobacter pylori eradication. Long-term results after se-
quential histologic and molecular follow-up. Haematologica 2001;
86: 609–617
21 Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, Megraud
F, Palazzo L, de Mascarel A, Molina T, Rambaud JL. Predictive
factors for regression of gastric MALT lymphoma after anti-
Helicobacter pylori treatment. Gut 2001; 48: 297–303
22 Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB,
Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE,
Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti
S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas
FF. Antibiotic treatment of gastric lymphoma of mucosa-asso-
ciated lymphoid tissue: An uncontrolled trial. Ann Intern Med
1999; 131: 88-95
23 Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa
K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M. Pre-
dictive value of endoscopic ultrasonography for regression of gas-
tric low grade and high grade MALT lymphomas after eradica-
tion of Helicobacter pylori. Gut 2001; 48: 454–460
24 Cheng H, Wang J, Zhang CS, Yan PS, Zhang XH, Hu PZ, Ma FC.
Clinicopathologic study of mucosa-associated lymphoid tissue
lymphoma in gastroscopic biopsy. World J Gastroenterol 2003; 9:
1270-1272
25 Levy M, Copie-Bergman C, Traulle C, Lavergne-Slove A, Brousse
N, Flejou JF, de Mascarel A, Hemery F, Gaulard P, Delchier JC.
Conservative treatment of primary gastric low-grade B-cell lym-
phoma of mucosa-associated lymphoid tissue: predictive factors
of response and outcome. Am J Gastroenterol 2002; 97: 292-297
26 Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malig-
nant lymphomas of the mucosa-associated lymphoid tissue: fac-
tors relevant to prognosis. Gastroenterology 1992; 102: 1628-1638
27 Park HC, Park W, Hahn JS, Kim CB, Lee YC, Noh JK, Suh CO.
Low grade MALT lymphoma of the stomach: treatment outcome
with radiotherapy alone. Yonsei Med J 2002; 43: 601-606
28 Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-
associated lymphoid tissue lymphoma of the stomach with ra-
diation alone. J Clin Oncol 1998; 16: 1916-1921
29 Taal BG, den Hartog Jager FC, Burgers JM, van Heerde P, Tio
TL. Primary non-Hodgkin’s lymphoma of the stomach: Chang-
ing aspects and therapeutic choices. Eur J Cancer Clin Oncol 1989;
25: 439–450
30 Seifert E, Schulte F, Weismuller J, de Mas CR, Stolte M. Endo-
scopic and bioptic diagnosis of malignant non-Hodgkin’s lym-
phoma of the stomach. Endoscopy 1993; 25: 497–501
31 Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Ito
M, Kamada T, Tanaka S, Uemura N, Yoshihara M, Sumii K,
Shimamoto F, Chayama K. Clinicopathological features of gas-
tric mucosa-associated lymphoid tissue lymphoma: a compari-
son with diffuse large B-cell lymphoma without a mucosa-asso-
ciated lymphoid tissue lymphoma component. J Gastroenterol
Hepatol 2001; 16: 734-739
32 Isaacson PG. Recent developments in our understanding of gas-
tric lymphomas. Am J Surg Pathol 1996; 20(Suppl): S1-7
Edited by Zhu LH and Wang XL
226                  ISSN 1007-9327      CN 14-1219/ R        World J Gastroenterol    January 15, 2004   Volume 10   Number 2
